Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns.
Travere Therapeutics grew its share prices by 40.78 percent week-on-week, as investors increased their positions after securing the approval of the Food and Drug Administration (FDA) for its kidney disease treatment, Filspari.
In a statement earlier in the week, Travere Therapeutics Inc. (NASDAQ:TVTX) said that the FDA has given the green light for Filspari to treat patients aged 8 and above who are suffering from focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. It is the only medicine approved by the FDA to treat FSGS.
Photo by Roger Brown on Pexels
The approval followed the successful phase 3 study of the drug, which saw a 46 percent reduction in proteinuria at week 108, as compared with the 30 percent for those treated with the maximum labeled dose of irbesartan.
Travere Therapeutics Inc. (NASDAQ:TVTX) noted that Filspari demonstrated even greater improvements in patients without nephrotic syndrome, versus the maximum labeled dose of irbesartan across proteinuria and eGFR.
“This approval reflects years of perseverance and our belief that those living with FSGS deserve better. It also builds on our leadership and progress in rare kidney diseases, expanding Filspari’s potential reach to more than 100,000 people in the US with FSGS and IgAN (IgA nephropathy) who need better treatment options,” said Travere Therapeutics Inc. (NASDAQ:TVTX) President and CEO Eric Dube.
“Filspari will be available for nephrologists to immediately prescribe to individuals with FSGS. We are profoundly grateful to the patients, caregivers, investigators, healthcare providers, regulators and advocates who made this moment possible,” he noted.
While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
